loading
Schlusskurs vom Vortag:
$1.15
Offen:
$1.16
24-Stunden-Volumen:
1.67M
Relative Volume:
0.76
Marktkapitalisierung:
$258.04M
Einnahmen:
$8.95M
Nettoeinkommen (Verlust:
$-21.49M
KGV:
-9.4167
EPS:
-0.12
Netto-Cashflow:
$-29.24M
1W Leistung:
+17.60%
1M Leistung:
+5.61%
6M Leistung:
+77.67%
1J Leistung:
+8.65%
1-Tages-Spanne:
Value
$1.12
$1.21
1-Wochen-Bereich:
Value
$0.9296
$1.21
52-Wochen-Spanne:
Value
$0.3651
$1.21

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name
Firmenname
Lineage Cell Therapeutics Inc
Name
Telefon
510-871-4188
Name
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Name
Mitarbeiter
76
Name
Twitter
@LineageCell
Name
Nächster Verdiensttermin
2025-03-10
Name
Neueste SEC-Einreichungen
Name
LCTX's Discussions on Twitter

Vergleichen Sie LCTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LCTX
Lineage Cell Therapeutics Inc
1.13 262.61M 8.95M -21.49M -29.24M -0.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-20 Eingeleitet Craig Hallum Buy
2022-11-02 Eingeleitet Robert W. Baird Outperform
2022-06-14 Eingeleitet B. Riley Securities Buy
2021-08-19 Eingeleitet Noble Capital Markets Outperform
2021-03-31 Eingeleitet Cantor Fitzgerald Overweight

Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten

pulisher
Jul 25, 2025

Is Lineage Cell Therapeutics Inc. a good long term investmentFree Smart Trading Workshop - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lineage Cell Therapeutics Inc. Stock Analysis and ForecastTremendous growth opportunities - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Lineage Cell Therapeutics Inc. stockPhenomenal investment performance - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 23, 2025

What drives Lineage Cell Therapeutics Inc. stock priceFree Consultation - Autocar Professional

Jul 23, 2025
pulisher
Jul 16, 2025

Stem Cell Therapy Market Attracts Investment in Neuro, Onco & - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Why Lineage Cell Therapeutics Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Lineage Cell Therapeutics Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Lineage Cell Therapeutics Inc. stock performs during market volatilityBreakout Momentum Stocks - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Spinal Cord Injury Pipeline 2025: MOA And ROA Insights, Clinical Trials Status, And Key Companies Involved By Delveinsight Stemcyte, Nervgen Pharma, VA Office Of Research And Development, Kessler - MenaFN

Jul 14, 2025
pulisher
Jul 11, 2025

Cell Therapy Manufacturing Market Exclusive Report with - openPR.com

Jul 11, 2025
pulisher
Jul 03, 2025

Cell Therapy Manufacturing Market In-depth Insights, Business - openPR.com

Jul 03, 2025
pulisher
Jul 02, 2025

Lineage Cell Therapeutics shareholders approve board slate and equity plan amendment - Investing.com

Jul 02, 2025
pulisher
Jun 23, 2025

Lineage Cell stock holds steady as Roche presents positive 3-year data - Investing.com UK

Jun 23, 2025
pulisher
Jun 20, 2025

Lineage Cell Therapeutics (LCTX) Drops 1.65% Amid OpRegen Trial Hype - AInvest

Jun 20, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

Rising Demand in Allogeneic Stem Cells Market USD 2.0Bn By 2031 - openPR.com

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Cell Therapy Manufacturing Market Exclusive Report with Detailed Study Analysis | WuXi AppTec, Healios Ltd. - newstrail.com

Jun 10, 2025
pulisher
Jun 09, 2025

Lineage Cell Therapeutics appoints new auditor - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Has $44,000 Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Buys 142,965 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace

Jun 05, 2025
pulisher
Jun 04, 2025

Deutsche Bank AG Has $87,000 Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 04, 2025

Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):